Company profile
Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Avrukibart | phase2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07449702 | phase2 | recruiting | 2026-02-23 | 2030-05-01 | Oruka Therapeutics, Inc. | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis |
| NCT07290569 | phase2 | active_not_recruiting | 2025-12-03 | 2027-06-01 | Oruka Therapeutics, Inc. | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT07474792 | phase2 | recruiting | 2026-03-19 | 2027-10-01 | Oruka Therapeutics, Inc. | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT07090330 | phase2 | active_not_recruiting | 2025-07-18 | 2026-03-25 | Oruka Therapeutics, Inc. | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT06698939 | phase1 | completed | 2024-12-19 | 2026-03-13 | Oruka Therapeutics, Inc. | ORKA-001 in Healthy Volunteers |
FDA applications (0)
No records yet.